Recurrence of localized
prostate cancer following treatment can lead to lethal metastatic
castration-resistant
prostate cancer. Although numerous studies aimed at developing
biomarkers for predicting recurrence of localized
prostate cancer are promising, they have not yet led to useful applications. Dysregulation of
exportins (XPOs, nucleocytoplasmic transporters) associated with subcellular mislocalization of
proteins has been reported for various human
cancers. However, most of the XPOs have not been studied in
prostate cancer. In this study, we are the first to examine whether changes in expression of XPOs could be used as potential
biomarkers for recurrence of localized
prostate cancer. Using the oncomine database, gene expressions of 7 known XPOs by 1128 patient samples, obtained from 16 independent
prostate cancer patient cohorts, were analyzed. Relatively highly elevated expression of XPO6 (compared to
prostate cancer tissue) was found to be significantly associated with poor patient prognosis, in particular, with rapid recurrence in a clinical low risk group. As such, expression of XPO6 may be a potential prognostic
biomarker for predicting
prostate cancer recurrence.